
Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma
Acalabrutinib (Calquence) plus bendamustine (Treanda) and rituximab (Rituxan) has received approval from the EU as a frontline treatment for adult patients with previously untreated mantle cell lymphoma (MCL) ineligible for autologous hematopoietic stem …